Skip to main content
TipRanks
Go Ultimate75% OFF

Sinopharm Group Co (X2S1) Stock Price & Analysis

1 Followers

X2S1 Stock Chart & Stats

€9.55€0.00(0.00%)
At close: 5:30 PM GMT+1
€8.5€8.75€9Jun 23Sep 10
Day’s Range
EUR 9.55 - EUR 9.55
52-Week Range
EUR 8.05 - EUR 11.80
Previous Close
EUR 9.55
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 6.02B
Enterprise Value
EUR 23.42B
Total Cash (Recent Filing)
EUR 41.90B
Total Debt (Recent Filing)
EUR 81.32B
Price to Earnings (P/E)
6.3
Beta
0.33
Next Earnings
Mar 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
4.55%

Bulls Say, Bears Say

Bulls Say

Nationwide Healthcare Distribution Network

The nationwide distribution network gives Sinopharm broad access to institutional and retail healthcare customers. Its coverage across hospitals, clinics, pharmacies and providers supports recurring product flow and creates a durable platform for distributing medicines, devices and consumables at scale.

Broad Healthcare Product Portfolio

A broad product portfolio reduces reliance on any single healthcare category and allows the company to serve multiple customer needs through the same distribution infrastructure. This breadth can support customer retention, cross-selling and resilience as demand shifts across healthcare products.

Positive Cash Generation

Consistently positive operating and free cash flow indicates that reported earnings generally convert into funding capacity. Although recent momentum weakened, this cash-generation record supports ongoing operations, working-capital needs and capital allocation without relying entirely on external financing.

Bears Say

Recent Revenue Contraction

Recent revenue contraction marks a deterioration from the stronger growth seen during 2021–2023. If weaker sales persist, the company may have less operating leverage and reduced capacity to absorb distribution costs, while slower volume growth could limit improvement in earnings over the next several quarters.

Structural Margin Compression

Falling gross and EBITDA margins show that profitability has weakened beyond the recent revenue slowdown. Because distribution earnings are already modest, sustained margin pressure could materially constrain profit growth, reduce reinvestment capacity and leave less cushion against pricing or cost pressures.

Higher Leverage And Weaker Returns

The sharp year-over-year increase in leverage reduces financial flexibility at the same time that returns on equity have weakened. Higher debt exposure can make future funding and capital allocation more constrained, while lower ROE signals that the enlarged equity and asset base is generating less shareholder return.

Sinopharm Group Co News

X2S1 FAQ

What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was €8.05 and its highest was €11.80 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is €6.02B.
When is Sinopharm Group Co’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sinopharm Group Co’s earnings last quarter?
Sinopharm Group Co released its earnings results on Aug 23, 2026. The company reported €0.709 earnings per share for the quarter.
Is Sinopharm Group Co overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co does not currently pay dividends.
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Sinopharm Group Co reported an EPS of €0.709 in its last earnings report. Following the earnings report the stock price went down -0.875%.
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in DE:X2S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology